Market Closed -
Nasdaq Stockholm
11:24:42 2024-05-24 am EDT
|
5-day change
|
1st Jan Change
|
2.2
SEK
|
-3.08%
|
|
+20.88%
|
-29.26%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
154.8
|
342.2
|
224.7
|
257
|
193.1
|
140.9
|
-
|
Enterprise Value (EV)
1 |
154.8
|
342.2
|
183
|
257
|
164
|
98.44
|
140.9
|
P/E ratio
|
-3.04
x
|
-4.79
x
|
-2.89
x
|
-3.51
x
|
-
|
7.57
x
|
-2.06
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
2,348,959
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
2,348,959
x
|
EV / EBITDA
|
-
|
-
|
-2.37
x
|
-
|
-4.34
x
|
-2.12
x
|
-20.1
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
53.6
x
|
5.79
x
|
-2.17
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
1.86%
|
17.3%
|
-46.1%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
37,766
|
37,766
|
37,766
|
62,087
|
62,087
|
62,087
|
-
|
Reference price
2 |
4.100
|
9.060
|
5.950
|
4.140
|
3.110
|
2.270
|
2.270
|
Announcement Date
|
2/28/20
|
2/26/21
|
2/24/22
|
2/24/23
|
2/27/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.00006
|
EBITDA
1 |
-
|
-
|
-77.35
|
-
|
-37.79
|
-46.5
|
-7
|
EBIT
1 |
-
|
-
|
-77.93
|
-
|
-38.26
|
-46.5
|
-7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-11,666,666.67%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-77.78
|
-
|
-37.17
|
-46.5
|
-7
|
Net income
1 |
-50.86
|
-71.37
|
-77.78
|
-56.24
|
-37.17
|
-46.5
|
-7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-11,666,666.67%
|
EPS
2 |
-1.350
|
-1.890
|
-2.060
|
-1.180
|
-
|
0.3000
|
-1.100
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
3.057
|
17
|
-65
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-108,333,333.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/20
|
2/26/21
|
2/24/22
|
2/24/23
|
2/27/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
41.7
|
-
|
29.1
|
42.5
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
3.06
|
17
|
-65
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.05
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/20
|
2/26/21
|
2/24/22
|
2/24/23
|
2/27/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -29.26% | 13.13M | | +12.08% | 116B | | +12.99% | 106B | | -9.42% | 23.89B | | -1.69% | 21.58B | | -10.60% | 18.96B | | -41.25% | 16.96B | | -14.55% | 16.33B | | +6.51% | 14.14B | | +30.55% | 12.02B |
Bio Therapeutic Drugs
|